Michael Yee of RBC Capital Markets, for instance, expects the price will be $225,000 to $250,000 a year.
Vertex has already had to justify its $300,000-plus Kalydeco price tag. Payer pressure may ramp up if Orkambi--which Vertex thinks can help it reach 10 times as many patients--is priced similarly
so if I understand this correctly, they got approval for a drug hat competes with there own drug ? and they sell it for cheaper ? so basicly they give you vile number 1 with red liquid for $300 a shot or vile 2 with blue liquid for $200 a shot ...either for same sickness ???
UBS analyst Matthew Roden reiterated a Buy rating and $145 price target on Vertex Pharma (NASDAQ: VRTX) Wednesday, ahead of the July 5th PDUFA for Orkambi. The firm believes pricing of the cystic fibrosis drug could drive upward revisions